IsoPlexis develops proprietary single-cell functional proteomic technology, including proteomic barcode chips and software-enabled IsoLight and IsoSpark detection systems, to profile secreted proteomes, phosphoproteomes, and metabolomes from single cells. Its end-to-end solutions are used to phenotype immune cells and connect in vivo biology to therapeutic development, with applications in cancer immunotherapy, cell and gene therapy, COVID-19, and autoimmune disease. The company says it has placed more than 100 systems and employs over 200 people, and its products are used by 15 of the top 15 global pharmaceutical companies and by approximately 45% of comprehensive cancer centers. IsoPlexis plans to use the financing to expand global commercial and R&D teams, increase operational capacity to meet demand, and accelerate its next-generation single-cell biology product development roadmap. The company positions its platform to provide new layers of biological data and help predict complex responses to therapies and disease. IsoPlexis is a Branford, Conn.-based developer of single-cell functional proteomics technology. Its core product is the IsoLight single-cell proteomic analysis platform, used globally by biotech, pharma, and academic medical centers to address challenges in cell therapy, cancer immunology, and inflammatory disease. The company says its systems accelerate research into cancer and a range of the world’s toughest diseases. IsoPlexis has expanded its operational, manufacturing, and commercial teams across the US, Europe, and Asia and employs 130 people. It intends to use recent funding to drive global commercial expansion of the IsoLight platform and in 2020 plans to expand applications and release products addressing innate & myeloid function, tumor cell signaling, and other high-need research areas. The company is led by CEO and co-founder Sean Mackay. IsoPlexis develops integrated single-cell detection systems and biomarkers that reveal unique immune signals in small subsets of cells to advance immunotherapies and targeted therapies. Its IsoLight system launched in 2018 and has been deployed at cancer centers and biopharma organizations across the US, Europe and China. Customers have released datasets using the IsoPlexis platform on CAR-T, TCR-T, CRISPR-edited T cells, tumor-infiltrating lymphocytes and checkpoint-immunotherapy patient samples; its single-cell polyfunctional strength product predicted CAR T-cell therapy responses pre-therapy. The company is preparing multiple 2019 product launches including single-cell polyfunctional inflammation solutions for neuroinflammation and autoimmunity, innate and myeloid cell solutions, single-cell energy-state assays, and tumor resistance assays. IsoPlexis leverages an internal application engine and partnerships with university professors and co-founders to build new single-cell products. The company has 105 employees and plans to expand its global operational, manufacturing, and commercial teams across the US, Europe and Asia. IsoPlexis Corporation, a Branford, Conn.-based life science company, raised $13.5M in a Series B financing. The company intends to use the funds for continued product development and marketing to expand use of its IsoCode assay and IsoLight system by trial centers and biopharmaceutical companies focused on oncology and other disease areas. Led by CEO and co-founder Sean Mackay, IsoPlexis uses a next-generation diagnostic and therapeutic platform to identify patient responses at the single-cell level. The IsoCode assay and IsoLight can capture 42 different secreted proteins per cell across thousands of single cells simultaneously, producing a precise functional profile of tumor-reactive T-cells in each patient. That functional profiling enables researchers to better predict and understand complex cancer patient response. The system is also being used to advance research and therapeutic development in infectious diseases, multiple sclerosis, systemic lupus and other high-need areas. IsoPlexis develops a proprietary single-cell multiplexing immunoassay and accompanying software suite that enables detailed biological characterization of important immune and cancer cell subsets within heterogeneous populations. Its platform is intended to help discover novel biomarkers and more accurately test molecules for clinical activity against heterogeneous cell subsets. The company is led by CEO Sean Mackay and is a Yale startup supported by the Yale Entrepreneurial Institute and Office of Cooperative Research; its technology originates from the laboratory of Dr. Rong Fan. IsoPlexis planned engineering and software updates and a beta product finalization as near-term product objectives. The company also aimed to support additional hospital and clinical case studies as part of its development pathway. Funding needs described include product development and working capital to advance commercial readiness.

Total raised

$194M

Funding rounds

6

Latest round

Series D

Latest activity

Jan 2021